Basel, Basel, Switzerland
1 - Passionate about and experienced in enabling the business to deliver on patients’ needs via program, project and process management in the Pharmaceutical and Diagnostics industry. 2 - Pharma - in depths experience: - Oncology, neuroscience, rheumatology/ immunology and antibacterials - PhII to PhIII, PhIII & IV, from patent expiration to solution phase out. 3 - Diagnostics - in depths experience:: - Companion Diagnostics (CDx) and regular in-vitro Diagnostics (IVD) - Across the whole solution life cycle. 4 - Robust knowledge of the end-to-end development & commercialization process for drugs as well as the in-vitro immunodiagnostics (IVD) / companion immunodiagnostics (CDx) design control process. 5 - Recognized as a strategic thought partner to build and operationalize strategies via translation into efficient and effective teamwork. 6 - Used to work successfully in a global matrix environment, handle pressure and short time lines while creating patient benefit, business value and strong stakeholder buy-in. 7 - PhD-MBA, MAE, PMP-certified, awarded for professional and academic achievements.
+ Huntington's Disease / Tominersen
+ Covered program: TL1A/ afimkibart
+ Covered programs: Venclexta/ Venetoclax; Management of CRS - Cytokine Release Syndrome (prevent, predict, treat)
- Identified breakthrough innovation platform (incl. development of preliminary business plan) - Selected as best of 5 competing teams
- Developed commercialization plan for patented diagnostic test - Analyzed RVL-internal patenting and commercialization process for potential improvements
- Analyzed current solution development process - Recommended process improvements and outlined implementation strategy
- Acquired consulting projects for the club - Managed consulting project portfolio to ensure meeting scope and timeline - Lead project to design R&D project monitoring process for a major business unit of Roche Diagnostics (Switzerland) - Lead team to organize & conduct major career fair at Hult IBS (14 guest speakers and 90 attendees)